Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

SOLV vs BDX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SOLV
Solventum Corporation

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$12.32B
5Y Perf.+2.1%
BDX
Becton, Dickinson and Company

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$52.45B
5Y Perf.-5.4%

SOLV vs BDX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SOLV logoSOLV
BDX logoBDX
IndustryMedical - Care FacilitiesMedical - Instruments & Supplies
Market Cap$12.32B$52.45B
Revenue (TTM)$8.26B$21.92B
Net Income (TTM)$1.43B$1.76B
Gross Margin53.7%45.8%
Operating Margin25.5%12.4%
Forward P/E11.0x11.6x
Total Debt$5.04B$19.18B
Cash & Equiv.$878M$851M

SOLV vs BDXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SOLV
BDX
StockMar 24May 26Return
Solventum Corporati… (SOLV)100102.1+2.1%
Becton, Dickinson a… (BDX)10094.6-5.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: SOLV vs BDX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BDX leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Solventum Corporation is the stronger pick specifically for valuation and capital efficiency and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
SOLV
Solventum Corporation
The Value Play

SOLV is the clearest fit if your priority is value and quality.

  • Lower P/E (11.0x vs 11.6x)
  • 17.3% margin vs BDX's 8.0%
  • 10.0% ROA vs BDX's 3.2%, ROIC 16.9% vs 4.3%
Best for: value and quality
BDX
Becton, Dickinson and Company
The Income Pick

BDX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 0.66, yield 2.9%
  • Rev growth 8.2%, EPS growth -0.5%, 3Y rev CAGR 5.0%
  • 72.9% 10Y total return vs SOLV's -11.2%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthBDX logoBDX8.2% revenue growth vs SOLV's 0.9%
ValueSOLV logoSOLVLower P/E (11.0x vs 11.6x)
Quality / MarginsSOLV logoSOLV17.3% margin vs BDX's 8.0%
Stability / SafetyBDX logoBDXBeta 0.66 vs SOLV's 1.05, lower leverage
DividendsBDX logoBDX2.9% yield; 1-year raise streak; the other pay no meaningful dividend
Momentum (1Y)BDX logoBDX+45.3% vs SOLV's +8.5%
Efficiency (ROA)SOLV logoSOLV10.0% ROA vs BDX's 3.2%, ROIC 16.9% vs 4.3%

SOLV vs BDX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SOLVSolventum Corporation
FY 2025
Product
100.0%$6.3B
BDXBecton, Dickinson and Company
FY 2025
Medical
52.5%$11.5B
Interventional
23.9%$5.2B
Life Sciences
23.7%$5.2B

SOLV vs BDX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSOLVLAGGINGBDX

Income & Cash Flow (Last 12 Months)

Evenly matched — SOLV and BDX each lead in 3 of 6 comparable metrics.

BDX is the larger business by revenue, generating $21.9B annually — 2.7x SOLV's $8.3B. SOLV is the more profitable business, keeping 17.3% of every revenue dollar as net income compared to BDX's 8.0%. On growth, BDX holds the edge at +1.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSOLV logoSOLVSolventum Corpora…BDX logoBDXBecton, Dickinson…
RevenueTrailing 12 months$8.3B$21.9B
EBITDAEarnings before interest/tax$2.9B$5.2B
Net IncomeAfter-tax profit$1.4B$1.8B
Free Cash FlowCash after capex-$203M$2.6B
Gross MarginGross profit ÷ Revenue+53.7%+45.8%
Operating MarginEBIT ÷ Revenue+25.5%+12.4%
Net MarginNet income ÷ Revenue+17.3%+8.0%
FCF MarginFCF ÷ Revenue-2.5%+12.0%
Rev. Growth (YoY)Latest quarter vs prior year-3.0%+1.6%
EPS Growth (YoY)Latest quarter vs prior year-91.0%+28.8%
Evenly matched — SOLV and BDX each lead in 3 of 6 comparable metrics.

Valuation Metrics

SOLV leads this category, winning 4 of 5 comparable metrics.

At 8.0x trailing earnings, SOLV trades at a 68% valuation discount to BDX's 24.8x P/E. On an enterprise value basis, SOLV's 6.2x EV/EBITDA is more attractive than BDX's 14.0x.

MetricSOLV logoSOLVSolventum Corpora…BDX logoBDXBecton, Dickinson…
Market CapShares × price$12.3B$52.4B
Enterprise ValueMkt cap + debt − cash$16.5B$70.8B
Trailing P/EPrice ÷ TTM EPS8.00x24.83x
Forward P/EPrice ÷ next-FY EPS est.10.97x11.59x
PEG RatioP/E ÷ EPS growth rate1.50x
EV / EBITDAEnterprise value multiple6.17x14.04x
Price / SalesMarket cap ÷ Revenue1.48x2.40x
Price / BookPrice ÷ Book value/share2.47x1.64x
Price / FCFMarket cap ÷ FCF19.64x
SOLV leads this category, winning 4 of 5 comparable metrics.

Profitability & Efficiency

SOLV leads this category, winning 7 of 9 comparable metrics.

SOLV delivers a 30.7% return on equity — every $100 of shareholder capital generates $31 in annual profit, vs $7 for BDX. BDX carries lower financial leverage with a 0.76x debt-to-equity ratio, signaling a more conservative balance sheet compared to SOLV's 1.00x. On the Piotroski fundamental quality scale (0–9), BDX scores 7/9 vs SOLV's 6/9, reflecting strong financial health.

MetricSOLV logoSOLVSolventum Corpora…BDX logoBDXBecton, Dickinson…
ROE (TTM)Return on equity+30.7%+6.9%
ROA (TTM)Return on assets+10.0%+3.2%
ROICReturn on invested capital+16.9%+4.3%
ROCEReturn on capital employed+19.0%+5.4%
Piotroski ScoreFundamental quality 0–967
Debt / EquityFinancial leverage1.00x0.76x
Net DebtTotal debt minus cash$4.2B$18.3B
Cash & Equiv.Liquid assets$878M$851M
Total DebtShort + long-term debt$5.0B$19.2B
Interest CoverageEBIT ÷ Interest expense6.55x4.65x
SOLV leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

BDX leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in BDX five years ago would be worth $11,037 today (with dividends reinvested), compared to $8,875 for SOLV. Over the past 12 months, BDX leads with a +45.3% total return vs SOLV's +8.5%. The 3-year compound annual growth rate (CAGR) favors BDX at -0.1% vs SOLV's -3.9% — a key indicator of consistent wealth creation.

MetricSOLV logoSOLVSolventum Corpora…BDX logoBDXBecton, Dickinson…
YTD ReturnYear-to-date-10.1%-4.9%
1-Year ReturnPast 12 months+8.5%+45.3%
3-Year ReturnCumulative with dividends-11.2%-0.4%
5-Year ReturnCumulative with dividends-11.2%+10.4%
10-Year ReturnCumulative with dividends-11.2%+72.9%
CAGR (3Y)Annualised 3-year return-3.9%-0.1%
BDX leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SOLV and BDX each lead in 1 of 2 comparable metrics.

BDX is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than SOLV's 1.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SOLV currently trades 80.5% from its 52-week high vs BDX's 70.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSOLV logoSOLVSolventum Corpora…BDX logoBDXBecton, Dickinson…
Beta (5Y)Sensitivity to S&P 5001.05x0.66x
52-Week HighHighest price in past year$88.20$205.52
52-Week LowLowest price in past year$62.38$100.31
% of 52W HighCurrent price vs 52-week peak+80.5%+70.4%
RSI (14)Momentum oscillator 0–10054.630.5
Avg Volume (50D)Average daily shares traded1.3M2.5M
Evenly matched — SOLV and BDX each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates SOLV as "Buy" and BDX as "Buy". Consensus price targets imply 37.7% upside for SOLV (target: $98) vs 19.4% for BDX (target: $173). BDX is the only dividend payer here at 2.88% yield — a key consideration for income-focused portfolios.

MetricSOLV logoSOLVSolventum Corpora…BDX logoBDXBecton, Dickinson…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$97.80$172.85
# AnalystsCovering analysts1133
Dividend YieldAnnual dividend ÷ price+2.9%
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS$4.17
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.9%
Insufficient data to determine a leader in this category.
Key Takeaway

SOLV leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). BDX leads in 1 (Total Returns). 2 tied.

Best OverallSolventum Corporation (SOLV)Leads 2 of 6 categories
Loading custom metrics...

SOLV vs BDX: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is SOLV or BDX a better buy right now?

For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.

2% revenue growth year-over-year, versus 0. 9% for Solventum Corporation (SOLV). Solventum Corporation (SOLV) offers the better valuation at 8. 0x trailing P/E (11. 0x forward), making it the more compelling value choice. Analysts rate Solventum Corporation (SOLV) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SOLV or BDX?

On trailing P/E, Solventum Corporation (SOLV) is the cheapest at 8.

0x versus Becton, Dickinson and Company at 24. 8x. On forward P/E, Solventum Corporation is actually cheaper at 11. 0x.

03

Which is the better long-term investment — SOLV or BDX?

Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +10.

4%, compared to -11. 2% for Solventum Corporation (SOLV). Over 10 years, the gap is even starker: BDX returned +72. 9% versus SOLV's -11. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SOLV or BDX?

By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.

66β versus Solventum Corporation's 1. 05β — meaning SOLV is approximately 60% more volatile than BDX relative to the S&P 500. On balance sheet safety, Becton, Dickinson and Company (BDX) carries a lower debt/equity ratio of 76% versus 100% for Solventum Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — SOLV or BDX?

By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.

2% versus 0. 9% for Solventum Corporation (SOLV). On earnings-per-share growth, the picture is similar: Solventum Corporation grew EPS 221. 7% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, BDX leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SOLV or BDX?

Solventum Corporation (SOLV) is the more profitable company, earning 18.

7% net margin versus 7. 7% for Becton, Dickinson and Company — meaning it keeps 18. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SOLV leads at 26. 2% versus 11. 8% for BDX. At the gross margin level — before operating expenses — SOLV leads at 53. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SOLV or BDX more undervalued right now?

On forward earnings alone, Solventum Corporation (SOLV) trades at 11.

0x forward P/E versus 11. 6x for Becton, Dickinson and Company — 0. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SOLV: 37. 7% to $97. 80.

08

Which pays a better dividend — SOLV or BDX?

In this comparison, BDX (2.

9% yield) pays a dividend. SOLV does not pay a meaningful dividend and should not be held primarily for income.

09

Is SOLV or BDX better for a retirement portfolio?

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 9% yield). Both have compounded well over 10 years (BDX: +72. 9%, SOLV: -11. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SOLV and BDX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SOLV is a mid-cap deep-value stock; BDX is a mid-cap quality compounder stock. BDX pays a dividend while SOLV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

SOLV

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Stocks Like

BDX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.1%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SOLV and BDX on the metrics below

Revenue Growth>
%
(SOLV: -3.0% · BDX: 1.6%)
Net Margin>
%
(SOLV: 17.3% · BDX: 8.0%)
P/E Ratio<
x
(SOLV: 8.0x · BDX: 24.8x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.